Assistant Professor, Pathology, UCSF School of Medicine

Pathology

Dr. Ronald Balassanian, MD


Ronald Balassanian, MD works in the field of Pathology. He studied medicine at NYU School of Medicine. Dr. Ronald Balassanian is also a published physician. He has 9 paper published. The most recent paper is: Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Ronald Balassanian is registered with Medicare.



Publications


Schools


Doctors Specialties


Accepted Insurances


Education


Hospital


Helpful Reviews


Give Anonymous Review


Medicare Facts


National Provider Identifier [NPI] 1043282379
Last Name Of The Provider BALASSANIAN
First Name Of The Provider RONALD
View All

Similar Doctors


Dr. Geung H. Ahn, MD
Dr. John D. Carney, MD
Dr. Walter E. Finkbeiner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
Dr. Barbara L. Haller, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
Dr. Richard Garcia-Kennedy, MD
This Doctor is OpenDoctor Recommended.
Dr. Gioia Iezza, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
Dr. Joseph T. Rabban III, MD
This Doctor is OpenDoctor Recommended.
Dr. Kirk D. Jones, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
Dr. Ana I. Quiroga, MD
This Doctor is OpenDoctor Recommended.
Dr. Elham Khanafshar, MD
This Doctor is OpenDoctor Recommended.
Dr. Rema A. Rao, MD
This Doctor is OpenDoctor Recommended.
Dr. Werner Rosenau, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
Dr. Gerald L. Schall, MD
This Doctor is OpenDoctor Recommended.
Dr. Christine D. Nicoll, MD
This Doctor is OpenDoctor Recommended.
Dr. Zohreh L. Tabatabai, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
Dr. Benjamin D. Buelow, MD
This Doctor is OpenDoctor Recommended.
Dr. Amy P. Hart, MD
This Doctor is OpenDoctor Recommended.
Dr. Vijay A. George, MD
This Doctor is OpenDoctor Recommended.


Doctor Directory | TOS | twitter | FB | Angel | blog